STAT

NOVEMBER 18, 2023

The revolution started in silence. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science.

363

363

The Guardian - Pharmaceutical Industry

NOVEMBER 18, 2023

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection Obesity jab maker Novo Nordisk suggested to senior government officials that they could “profile” benefit claimants so that those most likely to return to work could be targeted with its weight-loss injections. Internal documents obtained by the Observer reveal that Pinder Sahota, corporate vice-president of Novo Nordisk UK, told the then health secretary Steve Barclay, England’s chief

Documentation 111

Documentation 111

STAT

NOVEMBER 18, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “ The end of affirmative action means it’s time to revise pre-med requirements ,” by David Velasquez The ability to do well in both general and organic chemistry as well as physics that requires calculus are cours

264

264

PharmaState Academy

NOVEMBER 18, 2023

This blog explores the leverages of real-world evidence (RWE) in the realm of Pharma Marketing at the Now & Next Summit in Pharma Marketing 2023. In this engaging panel discussion , esteemed experts delve into the vital role of real-world evidence (RWE) in driving success in the pharmaceutical domain. The session sheds light on how calculated risks and creative communication are imperative for success in this dynamic industry. – The panel is graced by eminent speakers including Dr Mon

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

Drug Patent Watch

NOVEMBER 18, 2023

This chart shows the pharmaceutical companies with the most patents in Russian Federation. Patents must be filed in each country (or, in some cases regional patent office) where patent protection… The post Which pharmaceutical companies have the most drug patents in Russian Federation? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 45

Pharmaceutical Companies Pharmaceutical Companies 45

PharmaState Academy

NOVEMBER 18, 2023

This blog provides one with the implications of the DPDP Act 2023 on the Pharma Marketing domain at the Now & Next Summit in Pharma Marketing 2023. The panel introduces the DPDP Act of 2023 and emphasizes its importance to the pharmaceutical industry. The discussion is led by two experts – Ms. Varsha Rajesh – who’s a Member of Pharmaceutical, Lifesciences, and Digital Health Practice at Nishith Desai Associates – Legal & Tax Counseling Worldwide, and Ms.

52

52

Pharmaceutical Technology

NOVEMBER 18, 2023

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD).

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.

Biosimilars 40

Biosimilars Diabetes 40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections.

40

40

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Pharmaceutical Technology

NOVEMBER 18, 2023

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.

Diabetes 40

Diabetes 40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-4157 is a mrna vaccine commercialized by Merck, with a leading Phase II program in Metastatic Melanoma.

Vaccines 40

Vaccines 40

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept biosimilar is under clinical development by Amgen and currently in Phase III for Macular Edema.

Biosimilars 40

Biosimilars 40

Pharmaceutical Technology

NOVEMBER 18, 2023

CMK-389 is under clinical development by Novartis and currently in Phase II for Pulmonary Sarcoidosis.

40

40